Laser photobiomodulation (830 and 660 nm) in mast cells, VEGF, FGF, and CD34 of the musculocutaneous flap in rats submitted to nicotine
Nenhuma Miniatura disponível
Data
2017
Autores
Siqueira das Neves, Lais Mara
Marcondes Ferreira Leite, Gabriella de Paula
Marcolino, Alexandre Marcio
Pinfildi, Carlos Eduardo [UNIFESP]
Garcia, Sergio Britto
de Araujo, Joao Eduardo
de Oliveira Guirro, Elaine Caldeira
Orientadores
Tipo
Artigo
Título da Revista
ISSN da Revista
Título de Volume
Resumo
The aim of this study was to investigate the effect of laser photobiomodulation (PBM) on the viability of the transverse rectus abdominis musculocutaneous (TRAM) flap in rats subjected to the action of nicotine. We evaluated 60 albino Wistar rats, divided into six groups of ten animals. Group 1 (saline) underwent the surgical technique to obtain a TRAM flap
group 2 (laser 830 nm) underwent the surgical technique and was irradiated with a laser 830 nm
group 3 (laser 660 nm) underwent the surgical technique and was irradiated with a laser 660 nm
group 4 was treated with nicotine subcutaneously (2 mg/kg/2x/day/4 weeks) and underwent surgery
group 5 (nicotine + laser 830 nm) was exposed to nicotine, underwent the surgical technique, and was irradiated with a laser 830 nm
group 6 (nicotine + laser 660 nm) was exposed to nicotine, underwent the surgical technique, and was irradiated with a laser 660 nm. The application of PBM occurred immediately after surgery and on the two following days. The percentage of necrosis was assessed using the AxioVisionA (R) software. The number of mast cells (toluidine blue staining) was evaluated, and immunohistochemistry was performed to detect vascular endothelial growth factor expression (anti-VEGF-A), fibroblasts (anti-basic FGF), and neoformed vessels (anti-CD34). PBM with a wavelength of 830 nm increased the viability of the TRAM flap, with a smaller area of necrosis, increased number of mast cells, and higher expression of VEGF and CD34. PBM increases the viability of musculocutaneous flaps treated with to nicotine.
group 2 (laser 830 nm) underwent the surgical technique and was irradiated with a laser 830 nm
group 3 (laser 660 nm) underwent the surgical technique and was irradiated with a laser 660 nm
group 4 was treated with nicotine subcutaneously (2 mg/kg/2x/day/4 weeks) and underwent surgery
group 5 (nicotine + laser 830 nm) was exposed to nicotine, underwent the surgical technique, and was irradiated with a laser 830 nm
group 6 (nicotine + laser 660 nm) was exposed to nicotine, underwent the surgical technique, and was irradiated with a laser 660 nm. The application of PBM occurred immediately after surgery and on the two following days. The percentage of necrosis was assessed using the AxioVisionA (R) software. The number of mast cells (toluidine blue staining) was evaluated, and immunohistochemistry was performed to detect vascular endothelial growth factor expression (anti-VEGF-A), fibroblasts (anti-basic FGF), and neoformed vessels (anti-CD34). PBM with a wavelength of 830 nm increased the viability of the TRAM flap, with a smaller area of necrosis, increased number of mast cells, and higher expression of VEGF and CD34. PBM increases the viability of musculocutaneous flaps treated with to nicotine.
Descrição
Citação
Lasers In Medical Science. London, v. 32, n. 2, p. 335-341, 2017.